Who Generates Higher Gross Profit? BioMarin Pharmaceutical Inc. or Jazz Pharmaceuticals plc

Jazz Pharmaceuticals leads in gross profit growth over BioMarin.

__timestampBioMarin Pharmaceutical Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20146212760001055457000
Thursday, January 1, 20157378870001222277000
Friday, January 1, 20169072340001382587000
Sunday, January 1, 201710718600001508505000
Monday, January 1, 201811759480001769378000
Tuesday, January 1, 201913445820002033831000
Wednesday, January 1, 202013361830002214650000
Friday, January 1, 202113757600002653478000
Saturday, January 1, 202216123700003118857000
Sunday, January 1, 202318421610003398627000
Monday, January 1, 20242273680000
Loading chart...

Unlocking the unknown

BioMarin vs. Jazz: A Decade of Gross Profit Growth

In the competitive landscape of pharmaceuticals, BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc have been vying for dominance in gross profit generation over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has consistently outperformed BioMarin, with a staggering 222% increase in gross profit, peaking at approximately $3.4 billion in 2023. In contrast, BioMarin's gross profit grew by 196%, reaching around $1.8 billion in the same year.

A Closer Look at the Trends

Jazz Pharmaceuticals' strategic expansions and product innovations have propelled its gross profit to new heights, particularly noticeable from 2018 onwards, where it saw a 92% increase over five years. Meanwhile, BioMarin has shown steady growth, with a notable 51% rise from 2018 to 2023. This data highlights the dynamic nature of the pharmaceutical industry and the importance of strategic planning in achieving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025